These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15922148)

  • 21. Rituximab use in systemic lupus erythematosus pneumonitis and a review of current reports.
    Lim SW; Gillis D; Smith W; Hissaria P; Greville H; Peh CA
    Intern Med J; 2006 Apr; 36(4):260-2. PubMed ID: 16640745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD; Patey S; Brogan PA; Hasson N; Pilkington C; Woo P; Tullus K
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
    Gabriel L; Morley BJ; Rogers NJ
    Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case.
    Uthman I; Taher A; Abbas O; Menassa J; Ghosn S
    Dermatology; 2008; 216(3):257-9. PubMed ID: 18182821
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical trial design in systemic lupus erythematosus.
    Dall'Era M; Wofsy D
    Curr Opin Rheumatol; 2006 Sep; 18(5):476-80. PubMed ID: 16896285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New immune modulatory drugs for systemic lupus erythematosus--what can we expect?
    Davidson A
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):638-9. PubMed ID: 17133245
    [No Abstract]   [Full Text] [Related]  

  • 28. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus.
    Gordon C; Bertsias G; Ioannidis JP; Boletis J; Bombardieri S; Cervera R; Dostál C; Font J; Gilboe IM; Houssiau F; Huizinga TW; Isenberg D; Kallenberg CG; Khamashta MA; Piette JC; Schneider M; Smolen JS; Sturfelt G; Tincani A; Van Vollenhoven R; Boumpas DT
    Ann Rheum Dis; 2009 Apr; 68(4):470-6. PubMed ID: 18388158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological treatment of rare inflammatory rheumatic diseases].
    Baslund B
    Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.
    Chong BF; Mohan C
    Expert Opin Ther Targets; 2009 Oct; 13(10):1147-53. PubMed ID: 19670960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapies for systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Clin Exp Immunol; 2005 May; 140(2):205-12. PubMed ID: 15807843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus.
    Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2006 Feb; 5(2):153-5. PubMed ID: 16431350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.
    Zandman-Goddard G; Blank M; Shoenfeld Y
    Lupus; 2009 Sep; 18(10):884-8. PubMed ID: 19671787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG; Jones RB; Burns SM; Jayne DR
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE.
    Abdwani R; Mani R
    Lupus; 2009 Apr; 18(5):460-4. PubMed ID: 19318402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab: a promising therapy in systemic lupus erythematosus.
    Thatayatikom A; White AJ
    Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of biologicals for the therapy of lupus erythematosus.
    Neumann D; Tschernig T; Boraschi D
    Expert Rev Vaccines; 2007 Dec; 6(6):1001-11. PubMed ID: 18034656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.
    Tsujimura S; Saito K; Nakayamada S; Nakano K; Tanaka Y
    Arthritis Rheum; 2005 Jun; 52(6):1676-83. PubMed ID: 15934077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lupus mortality in Japan.
    Kataoka H; Koike T
    Autoimmun Rev; 2004 Aug; 3(6):421-2. PubMed ID: 15351309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.